Jessica A. Wisniewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessica A. Wisniewski has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Anton Y. Peleg
Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University
2 shared publications Luke V. Blakeway
Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Australia
2 shared publicationsAdam W. J. Jenney
Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia
1 shared publicationAmanda Dennison
Microbiology Unit, Alfred Hospital, Melbourne, Australia
1 shared publication- Amy W. Chung
Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
1 shared publication Ana Copaescu
Department of Infectious Diseases, Austin Health, Heidelberg, Australia
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
AMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction
Whole-genome sequencing (WGS) data are an invaluable resource for understanding antimicrobial resistance (AMR) mechanisms. However, WGS data are high-dimensional and the lack of standardized genomic representations is a key barrier to AMR phenotype prediction. To fully explore these high-resolution data, we propose AMR-GNN, a graph deep learning-based framework that integrates multiple genomic representations with graph neural networks (GNN) to enable AMR phenotype prediction from genomic sequence data. We test AMR-GNN with Pseudomonas aeruginosa, a clinically relevant Gram-negative bacterial pathogen known for its complex AMR mechanisms. We present AMR-GNN as a proof-of-concept framework designed to address several key problems in AMR phenotype prediction with data-driven machine learning (ML) approaches, including using multiple genomic representations to enhance performance, to mitigate the influence of clonal relationships and to identify informative biomarkers to provide explainability. Follow-up validation on the largest publicly available dataset spanning both Gram-negative and Gram-positive pathogens highlights AMR-GNN’s broad applicability in detecting AMR in diverse and clinically relevant pathogen-drug combinations.
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessAMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction
Whole-genome sequencing (WGS) data are an invaluable resource for understanding antimicrobial resistance (AMR) mechanisms. However, WGS data are high-dimensional and the lack of standardized genomic representations is a key barrier to AMR phenotype prediction. To fully explore these high-resolution data, we propose AMR-GNN, a graph deep learning-based framework that integrates multiple genomic representations with graph neural networks (GNN) to enable AMR phenotype prediction from genomic sequence data. We test AMR-GNN with Pseudomonas aeruginosa, a clinically relevant Gram-negative bacterial pathogen known for its complex AMR mechanisms. We present AMR-GNN as a proof-of-concept framework designed to address several key problems in AMR phenotype prediction with data-driven machine learning (ML) approaches, including using multiple genomic representations to enhance performance, to mitigate the influence of clonal relationships and to identify informative biomarkers to provide explainability. Follow-up validation on the largest publicly available dataset spanning both Gram-negative and Gram-positive pathogens highlights AMR-GNN’s broad applicability in detecting AMR in diverse and clinically relevant pathogen-drug combinations.
- Open Access
- 8 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Genomic dissection of endemic carbapenem resistance reveals metallo-beta-lactamase dissemination through clonal, plasmid and integron transfer
Infections caused by metallo-beta-lactamase-producing organisms (MBLs) are a global health threat. Our understanding of transmission dynamics and how MBLs establish endemicity remains limited. We analysed two decades of blaIMP-4 evolution in a hospital using sequence data from 270 clinical and environmental isolates (including 169 completed genomes) and identified the blaIMP-4 gene across 7 Gram-negative genera, 68 bacterial strains and 7 distinct plasmid types. We showed how an initial multi-species outbreak of conserved IncC plasmids (95 genomes across 37 strains) allowed endemicity to be established through the ability of blaIMP-4 to disseminate in successful strain-genetic setting pairs we termed propagators, in particular Serratia marcescens and Enterobacter hormaechei. From this reservoir, blaIMP-4 persisted through diversification of genetic settings that resulted from transfer of blaIMP-4 plasmids between bacterial hosts and of the integron carrying blaIMP-4 between plasmids. Our findings provide a framework for understanding endemicity and spread of MBLs and may have broader applicability to other carbapenemase-producing organisms.
- 8 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Open AccessGenomic dissection of endemic carbapenem resistance reveals metallo-beta-lactamase dissemination through clonal, plasmid and integron transfer
Infections caused by metallo-beta-lactamase-producing organisms (MBLs) are a global health threat. Our understanding of transmission dynamics and how MBLs establish endemicity remains limited. We analysed two decades of blaIMP-4 evolution in a hospital using sequence data from 270 clinical and environmental isolates (including 169 completed genomes) and identified the blaIMP-4 gene across 7 Gram-negative genera, 68 bacterial strains and 7 distinct plasmid types. We showed how an initial multi-species outbreak of conserved IncC plasmids (95 genomes across 37 strains) allowed endemicity to be established through the ability of blaIMP-4 to disseminate in successful strain-genetic setting pairs we termed propagators, in particular Serratia marcescens and Enterobacter hormaechei. From this reservoir, blaIMP-4 persisted through diversification of genetic settings that resulted from transfer of blaIMP-4 plasmids between bacterial hosts and of the integron carrying blaIMP-4 between plasmids. Our findings provide a framework for understanding endemicity and spread of MBLs and may have broader applicability to other carbapenemase-producing organisms.
- Open Access
- 19 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity
Respiratory tract infection with SARS-CoV-2 results in varying immunopathology underlying COVID-19. We examine cellular, humoral and cytokine responses covering 382 immune components in longitudinal blood and respiratory samples from hospitalized COVID-19 patients. SARS-CoV-2-specific IgM, IgG, IgA are detected in respiratory tract and blood, however, receptor-binding domain (RBD)-specific IgM and IgG seroconversion is enhanced in respiratory specimens. SARS-CoV-2 neutralization activity in respiratory samples correlates with RBD-specific IgM and IgG levels. Cytokines/chemokines vary between respiratory samples and plasma, indicating that inflammation should be assessed in respiratory specimens to understand immunopathology. IFN-α2 and IL-12p70 in endotracheal aspirate and neutralization in sputum negatively correlate with duration of hospital stay. Diverse immune subsets are detected in respiratory samples, dominated by neutrophils. Importantly, dexamethasone treatment does not affect humoral responses in blood of COVID-19 patients. Our study unveils differential immune responses between respiratory samples and blood, and shows how drug therapy affects immune responses during COVID-19.
- 19 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessSARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity
Respiratory tract infection with SARS-CoV-2 results in varying immunopathology underlying COVID-19. We examine cellular, humoral and cytokine responses covering 382 immune components in longitudinal blood and respiratory samples from hospitalized COVID-19 patients. SARS-CoV-2-specific IgM, IgG, IgA are detected in respiratory tract and blood, however, receptor-binding domain (RBD)-specific IgM and IgG seroconversion is enhanced in respiratory specimens. SARS-CoV-2 neutralization activity in respiratory samples correlates with RBD-specific IgM and IgG levels. Cytokines/chemokines vary between respiratory samples and plasma, indicating that inflammation should be assessed in respiratory specimens to understand immunopathology. IFN-α2 and IL-12p70 in endotracheal aspirate and neutralization in sputum negatively correlate with duration of hospital stay. Diverse immune subsets are detected in respiratory samples, dominated by neutrophils. Importantly, dexamethasone treatment does not affect humoral responses in blood of COVID-19 patients. Our study unveils differential immune responses between respiratory samples and blood, and shows how drug therapy affects immune responses during COVID-19.